| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisals TA517: Avelumab for treating metastatic Merkel cell carcinoma and TA691: Avelumab for untreated metastatic Merkel cell carcinoma |
|
Medicine details |
|
| Medicine name | avelumab (Bavencio®) |
| Formulation | 20 mg/ml concentrate for solution for infusion |
| Reference number | 2992 |
| Indication | Monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma |
| Company | Merck Serono Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/08/2017 |
| NICE guidance |
|